Skip Navigation


Hum. Reprod. Advance Access originally published online on August 26, 2006
Human Reproduction 2007 22(1):109-116; doi:10.1093/humrep/del340
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow All Versions of this Article:
22/1/109    most recent
del340v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Cédrin-Durnerin, I.
Right arrow Articles by Hugues, J.N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cédrin-Durnerin, I.
Right arrow Articles by Hugues, J.N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Effects of oral contraceptive, synthetic progestogen or natural estrogen pre-treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol

I. Cédrin-Durnerin1,7, B. Bständig2, I. Parneix3, V. Bied-Damon4, C. Avril5, C. Decanter6 and J.N. Hugues1

1 Service de Médecine de la Reproduction, Hôpital Jean Verdier, Assistance Publique—Hôpitaux de Paris, Université Paris XIII, Bondy 2 Hôpital de l’Archet, Nice 3 Clinique Jean Villar, Aquitaine santé—Médecine de la Reproduction, Bruges 4 Clinique Monplaisir, Lyon 5 Clinique St Antoine, Bois Guillaume and 6 Hôpital Jeanne De Flandre, Lille, France

7 To whom correspondence should be addressed at: Service de Médecine de la Reproduction, Hôpital Jean Verdier, Assistance Publique—Hôpitaux de Paris, Université Paris XIII, 93143 Bondy cedex, France. E-mail: isabelle.cedrin-durnerin{at}jvr.ap-hop-paris.fr

BACKGROUND: Steroid pre-treatments may be useful to program GnRH antagonist IVF/ICSI cycles. This prospective study assessed hormonal and ultrasound data collected during the free period after the discontinuation of three different pre-treatments to provide information on the optimal time interval required before starting stimulation. METHODS: Women were randomized to receive oral contraceptive pill (OCP) [ethinyl estradiol (E2) 30 µg + desogestrel 150 µg] (n = 21) or norethisterone 10 mg/day (n = 23) or 17-betaE2 4 mg/day (n = 25) or no pre-treatment (n = 24) for one cycle before IVF. Assessments were performed on post-treatment day (PD) 1, 3 and 5, or on spontaneous cycle day (CD) 1 and 3. RESULTS: After OCP and progestogen administration, FSH and LH concentrations shifted from strongly suppressed PD1 levels to PD5 values similar to those observed on CD1. Meanwhile, follicle sizes remained small up to PD5. In contrast, estrogen pre-treatment poorly reduced FSH levels on PD1 compared with OCP or progestogen. Consequently, follicle size was more heterogeneous. FSH rebound was maximal on PD3, whereas LH levels were slightly increased up to PD5. CONCLUSIONS: A 5-day free interval after OCP or progestogen offers the advantages of gonadotrophin recovery and homogeneous follicular cohort, whereas early FSH rebound occurring after estrogen pre-treatment argues for a short free period.

Key words: GnRH antagonist/natural estrogen/oral contraceptive pill/pre-treatment/progestogen


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
J.A. Huirne, R. Homburg, and C.B. Lambalk
Are GnRH antagonists comparable to agonists for use in IVF?
Hum. Reprod., November 1, 2007; 22(11): 2805 - 2813.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.